PEG-MGF

Pegylated Mechano Growth Factor

PEG-MGF (Pegylated Mechano Growth Factor) is a gh & growth research compound. Splice variant of IGF-1 (IGF-1Ec) that activates muscle satellite cells for local repair; PEGylation extends its short native half-life.

How PEG-MGF works

Splice variant of IGF-1 (IGF-1Ec) that activates muscle satellite cells for local repair; PEGylation extends its short native half-life.

Proposed benefits

Local muscle repair and satellite-cell activation post-training.

Where to get PEG-MGF

The evidence for PEG-MGF

Graded by what exists behind each claim.

Human clinical evidence

• No human trials: development stopped at preclinical, so the ceiling on any claim here is a rodent model — and these transfer poorly.

📊 Correlative data

• Used in place of MGF specifically to solve the half-life problem. Reported experience is of a broader, more systemic effect than local MGF, which is what the modification predicts.
• Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.

🧪 How the mechanism reads

• MGF with a polyethylene glycol chain attached, extending serum half-life from minutes to hours.
• PEGylation solves the delivery problem and arguably defeats the point. MGF's proposed role is a local, transient signal at a site of mechanical damage; making it circulate for hours converts a local repair cue into a systemic one, and nobody has shown that the satellite-cell effect survives the change.

Why an empty tier is not a verdict → · What community dosing logs are worth →

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What PEG-MGF actually does

The MGF page in this catalog already deals with the peptide: whether the free 24-residue E-domain exists in any animal Matheny 2010, and the receptor assays in which it activated nothing Janssen 2016 Fornaro 2014. This page is about the other half of the name. The subject here is the chain.

What a PEG chain is, physically. Polyethylene glycol is a chain of repeating CH₂CH₂O units: flexible, uncharged, extremely water-loving polymer. Each ethylene oxide unit holds two to three water molecules, so a PEG chain in solution is not a compact lump — it is a hydrated random coil that sweeps out a large volume. That single property produces both effects PEGylation is used for, and they pull in opposite directions.

Effect one: apparent size, which is what buys the half-life. Because the coil is hydrated and mobile, a PEG chain behaves hydrodynamically like a globular protein of roughly five to ten times its own molecular weight. A 20 kDa PEG occupies solution space like a 100–200 kDa protein. That is the whole trick, and it is why a modest chain can move a peptide from freely-filtered to essentially unfilterable at the kidney.

Effect two: steric shielding, which is what costs the activity. The same sweeping coil sits between the peptide and everything that wants to touch it. It obstructs proteases, which is desirable, and it obstructs receptors, which is not. The PEGylation literature frames this explicitly as a trade — PEG is used to raise solubility, stability, shelf-life and circulating time and to prevent aggregation, and bioactivity is the property being negotiated against Zuma 2022. There is no version of PEGylation that extends half-life without imposing some steric cost on binding. The engineering question is always how much, and the answer depends on chain mass, whether it is linear or branched, and how close the attachment point sits to the business end of the molecule.

And now the fact that should be at the top of every PEG-MGF product page and is on none of them: nobody publishes the PEG size. Not the mass. Not linear versus branched. Not the attachment chemistry — N-terminal, lysine amine, or cysteine-maleimide. Not the degree of PEGylation, meaning how many chains per peptide. Not the positional isomer distribution, which for amine chemistry is never a single product. Every one of those determines both the half-life and the activity loss, and none of them is stated for this compound anywhere.

Why that blank is not a technicality: it changes the dose by a factor of three. The MGF peptide is 24 residues, roughly 2.9 kDa. Attach a 5 kDa PEG and the conjugate is about 7.9 kDa, of which the peptide is 37% by mass. Attach a 20 kDa PEG and the conjugate is about 23 kDa, of which the peptide is 13%. So a labeled 200 mcg dose of ‘PEG-MGF’ delivers about 74 mcg of peptide in the first case and about 25 mcg in the second. On a molar basis, 200 mcg of unmodified MGF is about 69 nanomoles of peptide; 200 mcg of a 20 kDa conjugate is about 8.7 nanomoles — eight times less.

This site sells both at the same 200–400 mcg, as though they were two strengths of one idea. They are not even the same amount of peptide, and the conversion factor is a number nobody has published.

The receptor question, and why it cannot be answered for this molecule. The normal way to quantify the steric cost of a PEG is to measure receptor binding or a functional response before and after conjugation, and report the fold loss. That experiment is impossible here, because the starting value is zero. The unmodified 24-residue peptide produced no IGF-1 receptor activation at all in a kinase-receptor activation assay in which recombinant IGF-1 gave an EC50 of 0.86 nmol/L and the full-length pro-protein gave 7.83 nmol/L Janssen 2016, and it had no effect on myoblasts or primary muscle stem cells at concentrations up to 500 ng/mL Fornaro 2014. You cannot measure what a shield costs a molecule that was not hitting anything.

Cell, rodent, human — and where it stops

Step one, the chain in cells: nothing, for this conjugate. No published receptor assay, no binding constant, no functional cell result for PEGylated MGF in any system. The unmodified peptide has been tested and gave nothing Janssen 2016 Fornaro 2014; the PEGylated form has never been tested at all.

Step two, the chain in animals: nothing, for this conjugate. No rodent pharmacokinetics, no tissue distribution, no muscle study.

Step three, in humans: nothing. No trial, no case series, no plasma measurement.

So the honest translation chain for PEG-MGF is empty at every step, and what follows is the chain for PEGylation itself, on a molecule where somebody did the work.

The comparator, and it is a good one. Jintrolong is a PEGylated recombinant human growth hormone dosed weekly — the same design problem as PEG-MGF, on a peptide hormone, taken all the way through development. Cynomolgus monkeys received 0.3, 1 or 3 mg/kg/week for 52 weeks. The finding was vacuolation in the choroid plexus, dose-dependent, and only partially reversible after recovery periods of 104 or 157 weeks. In humans the clinical dose was 0.2 mg/kg/week, studied in a 360-patient phase III and a 3,000-patient phase IV with 26 weeks of treatment and three-year follow-up, and there was no statistically significant difference in adverse reaction incidence against daily non-PEGylated growth hormone Wu 2022.

That pair of results is the most useful thing anybody has published about chronic PEG dosing, and it needs reading in both directions. The monkey finding is real: PEG is not metabolized, it leaves the body essentially only through the kidney, and above the chain sizes that abolish glomerular filtration it necessarily lingers — the choroid plexus is where that shows up, and 104 weeks of recovery only partly cleared it. The human finding is equally real: at a dose fifteen times lower, across 3,360 patients and three years, PEG did not produce a detectable excess of adverse reactions. Chronic PEG accumulation is a demonstrated phenomenon whose clinical significance at therapeutic doses was tested and not found, which is a more interesting position than either ‘PEG is dangerous’ or ‘PEG is inert’.

The obstacles, named one at a time. (1) The conjugate has never been characterized, so no number on the label — dose, half-life, or peptide content — is traceable to a measurement. (2) The peptide underneath has no identified receptor Janssen 2016, so the usual PEGylation trade cannot even be quantified. (3) The Jintrolong comparison is a loan, not a result: different peptide, different chain, different dose, different route. (4) The route and the modification contradict each other, which is the next section. (5) The human biology this compound is sold on is messenger RNA in a needle biopsy after a leg extension Hameed 2003, which says a gene responds to load and says nothing about an injected polymer conjugate.

PEG-MGF pharmacokinetics — how much of it actually gets in

The catalog says ‘~48–72 hrs’. There is no published measurement behind that number in any species. Here is what would have to be true for it to be right.

The kidney is the whole story, so start there. The glomerular filtration barrier is a size-selective sieve with an effective pore radius of about 4 to 4.5 nm. Small solutes pass freely; filtration falls away steeply as hydrodynamic radius rises, and by about 60–70 kDa it is negligible — which is why albumin, 66 kDa and a Stokes radius near 3.5 nm, stays in the blood.

Where an unmodified 24-mer sits on that curve. At about 2.9 kDa it is far below any cutoff and is filtered essentially on first pass through the kidney. That, more than proteolysis, is why unmodified MGF is a minutes-scale molecule, and it is why PEGylating it was the obvious commercial move.

Now the arithmetic that the 48-to-72-hour claim implies. Because a hydrated PEG coil behaves like a protein of five to ten times its mass, lifting a peptide clear of glomerular filtration needs an apparent size above roughly 60 kDa — which means a chain of at least 10 to 20 kDa, and in marketed products usually a branched 40 kDa. A cheap 5 kDa chain gives an apparent size around 25–50 kDa, which is inside the filterable range: it would slow clearance from minutes to perhaps an hour or two and would not come close to two or three days. So the card’s half-life is only achievable with a chain several times the mass of the peptide it is attached to — a product that is 80 to 90% polymer by weight. Either the number is wrong, or the vial is mostly PEG. Both are worth knowing and neither is stated.

What degrades it, and the answer is unusual: not much. PEGylation is used precisely because the coil obstructs proteases Zuma 2022, so enzymatic hydrolysis of the peptide slows down. PEG itself is not metabolized at all — there is no human enzyme that depolymerizes it — so once the peptide is cleaved off or degraded, the polymer must still leave, and renal excretion is the only meaningful route. Above the filtration cutoff that route is slow, which is exactly the condition under which repeat dosing deposits polymer in tissue, as the choroid plexus vacuolation in a 52-week primate study showed Wu 2022. It is not a cytochrome substrate and carries no small-molecule interaction list.

The oral barrier. Absolute, and PEGylation does not help. Swallowed, the conjugate meets gastric acid and pancreatic proteases; the shield slows proteolysis but there is no transporter for a 23 kDa hydrated coil across the enterocyte, and hepatic first-pass extraction sits behind that. No oral form exists.

The injectable comparator, and here the modification and the route contradict each other. This is injected intramuscularly, post-workout, into the trained muscle, on the premise of a local repair cue — and the biology it borrows from is a transient local signal after mechanical loading Hameed 2003. A PEG chain does two things to an intramuscular injection at once, and they point in opposite directions. It slows diffusion out of the injection site, which raises and prolongs local concentration and supports the local claim. And it slows renal clearance of whatever does reach the blood, which converts the dose into a multi-day systemic exposure and defeats the local claim. Which of the two dominates for this conjugate has never been measured — it depends entirely on the chain size nobody publishes — and it is the single most answerable open question about this compound.

What would have to be true, and how you would know it was not

Four predictions. Three of them say the compound should do nothing measurable, which is what the mechanism implies, and the fourth is an identity test.

1. IGF-1 should not move, and PEGylation makes that more certain rather than less. Draw IGF-1 before starting and again at 6 to 8 weeks. The prediction is no change. The unmodified peptide does not activate the IGF-1 receptor Janssen 2016, and adding a steric shield can only reduce whatever binding exists Zuma 2022 — a shield cannot create affinity. Anyone reporting an IGF-1 rise on this compound alone has either found something three published assays missed, or is also running a growth hormone secretagogue, or has a vial containing something other than a PEGylated 24-mer.

2. Fasting insulin and glucose should be flat, and movement is a purity signal rather than a benefit. The full-length pro-IGF-1Ec activates both insulin receptor isoforms in vitro, at 73.11 and 35.10 nmol/L, with a maximal IR-B response exceeding insulin’s own Janssen 2016; the 24-residue fragment does not. Check fasting insulin and HbA1c at baseline and 8 weeks. Movement there points to a larger molecule than the label claims, and it is the cheapest identity check available.

3. The falsification one person can run in four weeks: inject one side only — and here PEGylation makes the test better. The entire rationale is local action at the trained muscle. Train both limbs identically, inject one, and measure the same thing on both — circumference at a marked point, and a limb-specific one-rep maximum or grip strength for an arm. A local agent must produce asymmetry; the prediction is that it will not. The interesting wrinkle is that if the PEG really does hold drug at the injection site, asymmetry should be easier to detect for PEG-MGF than for plain MGF, because the residence time at the site is longer. A within-subject comparison removes diet, sleep, training and expectation in one stroke, and a null result here is informative in a way no anecdote is.

4. Per microgram, PEG-MGF must be weaker than MGF — and if anybody reports the opposite, the labeling is wrong. At a matched 200 mcg dose, a 20 kDa conjugate delivers roughly one eighth the molar quantity of peptide that unmodified MGF does, and a 5 kDa conjugate roughly one third. So any honest comparison at equal milligrams should favor the unmodified peptide on immediate effect and favor the conjugate only on duration. A consistent report that PEG-MGF hits harder per microgram than MGF is not evidence of a better drug; it is evidence that one of the two vials does not contain what it says.

What nobody has tested yet

Four experiments, and the first three are ordinary analytical chemistry that nobody in this market has ever paid for.

1. Nobody has measured the PEG. Not its mass, not linear versus branched, not the attachment chemistry, not how many chains per peptide, not the positional isomer distribution. A single MALDI-TOF run on three vendor lots would give the conjugate mass, and subtracting the peptide mass gives the chain size directly. That one measurement would convert the half-life on this card from an assertion into an estimate with a basis, and it would tell buyers what fraction of what they paid for is polymer.

2. Nobody has measured the pharmacokinetics in anything. There are 0 published PK measurements of PEG-MGF in any species. A single rodent time-course — plasma over 96 hours after one intramuscular dose, with the injected muscle and the contralateral muscle assayed at the end — would produce both the half-life and the local-versus-systemic split in one experiment. It is a week of work and it has never been done for a compound sold for two decades.

3. Nobody can measure the receptor cost, and that is the strangest fact on this page. The standard way to quantify PEGylation is a fold-loss in binding or potency Zuma 2022. Here the unmodified peptide already produces no IGF-1 receptor activation Janssen 2016 and no effect in three muscle cell systems Fornaro 2014. The experiment that would characterize this product cannot be run until somebody first finds a receptor for the peptide — a labeled pull-down or membrane binding screen on myoblasts, which has also never been published.

4. Nobody has looked for anti-PEG antibodies in people using these compounds. Antibodies to PEG are a recognized class-level question for PEGylated therapeutics, and they matter because they accelerate clearance on repeat dosing — which would silently convert a claimed 48-to-72-hour depot back into a short-acting one after a few weeks. The comparable PEGylated hormone program monitored long-term safety across 3,360 patients and found no excess of adverse reactions against the non-PEGylated drug Wu 2022, but that is a different chain on a different molecule. In the research-peptide population, where PEGylated compounds are stacked and run for years, nobody has drawn a single sample.

PEG-MGF — its own safety story, not its class's

The shared block on this page is the growth hormone and IGF-1 safety story — insulin resistance, fluid retention, carpal tunnel, the acromegaly literature. Almost none of it is this compound’s risk profile, because the peptide has never been shown to activate the IGF-1 receptor Janssen 2016. Four risks are specific, and two of them belong to the polymer rather than to the peptide.

1. PEG accumulates, and that is measured rather than speculated. PEG is not metabolized by any human enzyme; renal excretion is its only real exit, and the chain sizes that produce a long half-life are precisely the ones the kidney handles slowly. In a 52-week primate study of a PEGylated growth hormone at 0.3, 1 and 3 mg/kg/week, the finding was dose-dependent vacuolation of the choroid plexus, only partially reversible after 104 or 157 weeks of recovery Wu 2022. That is the mechanism-derived risk of chronic PEG dosing, it is specific, and it is absent from every discussion of this compound.

2. And the human counterweight, stated just as plainly. At the clinical dose of 0.2 mg/kg/week, across a 360-patient phase III and a 3,000-patient phase IV with 26 weeks of treatment and three-year follow-up, there was no statistically significant difference in adverse reactions against daily non-PEGylated growth hormone Wu 2022. So the honest summary is: PEG accumulation is real at high repeated doses in monkeys, and was not detectable as harm in 3,360 humans at a fifteen-fold lower dose. Somebody running 200–400 mcg three to five times a week is at a far lower polymer load than either — which is genuinely reassuring, and is an argument nobody has bothered to make.

3. Identity risk is larger here than for the unmodified peptide. With plain MGF a buyer is guessing about one molecule. With this one they are also guessing about the chain mass, the attachment site, the number of chains and the isomer mix — none of which is disclosed, all of which change both duration and activity, and none of which produces a symptom that identifies it. There is no assay a buyer can run and no observable to check it against, because the expected effect is already indistinguishable from nothing Fornaro 2014.

4. The repeated intramuscular injection is a real harm and it is not about the molecule. The usage pattern is intramuscular dosing into the same trained muscle after training, three to five times a week for 4 to 8 weeks. Repeated injection into one site carries infection, sterile abscess and local fibrosis risk regardless of the contents — and a PEGylated conjugate is specifically designed to persist at that site longer than an unmodified peptide would.

What zero means. There are 0 published human studies, 0 published pharmacokinetic measurements and 0 published adverse events for PEG-MGF. No setting has ever existed in which an adverse event could have been recorded, which is not a safety record. The one compound in its family that was taken all the way through development was a different peptide with a different chain Wu 2022, and even it needed 3,360 patients to say what it said.

Sources read for this page

• Zuma LK, et al. Protein PEGylation: Navigating Recombinant Protein Stability, Aggregation, and Bioactivity. BioMed Research International 2022 · PMID 35924267
• Wu W, et al. PEGylated Recombinant Human Growth Hormone Jintrolong Exhibits Good Long-Term Safety in Cynomolgus Monkeys and Human Pediatric Growth Hormone Deficiency Patients. Frontiers in Endocrinology 2022 · PMID 35909512
• Janssen JA, et al. Potency of Full-Length MGF to Induce Maximal Activation of the IGF-I R Is Similar to Recombinant Human IGF-I at High Equimolar Concentrations. PLoS One 2016 · PMID 26991004
• Fornaro M, et al. Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. American Journal of Physiology: Endocrinology and Metabolism 2014 · PMID 24253050
• Matheny RW Jr, Nindl BC, Adamo ML. Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology 2010 · PMID 20130113
• Hameed M, Orrell RW, Cobbold M, Goldspink G, Harridge SDR. Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise. Journal of Physiology 2003 · PMID 12562960

PEG-MGF — safety, predicted from mechanism